Cartherics and Catalent Expand Commercial License Agreement

MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women's diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced p.